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Implications of metabolism-driven myeloid dysfunctions in
cancer therapy
Laura Strauss1, Valentina Guarneri2,3, Alessandra Gennari4 and Antonio Sica 5,6
Immune homeostasis is maintained by an adequate balance of myeloid and lymphoid responses. In chronic inflammatory states,
including cancer, this balance is lost due to dramatic expansion of myeloid progenitors that fail to mature to functional
inflammatory neutrophils, macrophages, and dendritic cells (DCs), thus giving rise to a decline in the antitumor effector lymphoid
response. Cancer-related inflammation orchestrates the production of hematopoietic growth factors and cytokines that perpetuate
recruitment and activation of myeloid precursors, resulting in unresolved and chronic inflammation. This pathologic inflammation
creates profound alterations in the intrinsic cellular metabolism of the myeloid progenitor pool, which is amplified by competition
for essential nutrients and by hypoxia-induced metabolic rewiring at the tumor site. Therefore, persistent myelopoiesis and
metabolic dysfunctions contribute to the development of cancer, as well as to the severity of a broad range of diseases, including
metabolic syndrome and autoimmune and infectious diseases. The aims of this review are to (1) define the metabolic networks
implicated in aberrant myelopoiesis observed in cancer patients, (2) discuss the mechanisms underlying these clinical
manifestations and the impact of metabolic perturbations on clinical outcomes, and (3) explore new biomarkers and therapeutic
strategies to restore immunometabolism and differentiation of myeloid cells towards an effector phenotype to increase host
antitumor immunity. We propose that the profound metabolic alterations and associated transcriptional changes triggered by
chronic and overactivated immune responses in myeloid cells represent critical factors influencing the balance between
therapeutic efficacy and immune-related adverse effects (irAEs) for current therapeutic strategies, including immune checkpoint
inhibitor (ICI) therapy.
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INTRODUCTION
Enhanced myelopoiesis is recognized as the primary factor that
drives inflammatory disorders, including cancer, and is character-
ized by aberrant differentiation of myeloid progenitors, with an
accumulation of dysfunctional myeloid cells endowed with
suppressive functions, including myeloid-derived suppressor cells
(MDSCs), tolerogenic dendritic cells (DCs), and tumor-associated
macrophages (TAMs).1
Hematopoietic stem cells (HSCs) activation in persistent low-
grade inflammation in cancer or overactivation (i.e., in acute
infections or sepsis) perpetuates and increases myelopoiesis at
the expense of lymphopoiesis, leading to expansion of a pool of
immature and dysfunctional myeloid cells1 that besiege and
exhaust antitumor immunity, thus resulting in local and systemic
host immunosuppression.2,3 This pathologic myelopoiesis, lead-
ing to pro-disease phenotypes, provides us with an unresolved
immunological paradox to date, since enhanced myeloid
recruitment and function in tumors or infections should
represent the front line of host defense and avoid disease
progression.
Multiple inflammatory insults drive “pathological myelopoi-
esis”,4 including pathogen-associated molecular patterns and
damage-associated molecular patterns,5 which are sensed by
pattern-recognition receptors.6 Innate immune cells activated
through PPRs provide the source for cytokines and myelopoietic
growth factors acting on myeloid progenitors. Among these
cytokines, the pleiotropic cytokines IL-1, tumor necrosis factor
(TNF), and interleukin-6 (IL-6) serve as key promoters of
emergency myelopoiesis by controlling the dynamics of transcrip-
tion factors involved in myeloid lineage fate decisions and
function.7 Growing evidence suggests that key transcription
factors of emergency myelopoiesis, such as PU.1, interferon
regulatory factors, CEBP/beta and RORC, in addition to driving
myelopoiesis, are expressed in adipose tissue and have a central
role in adipocyte differentiation, adipose inflammation, and insulin
resistance (IR).8–10 This sharing of transcription networks between
the adipose tissue and myeloid cells indicates that alterations in
metabolic homeostasis may have a profound impact on myelo-
poiesis and therefore coordinate immune responses to environ-
mental cues. Interestingly, studies show that low-grade
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inflammation in the adipose tissue and liver of elderly individuals
or patients with metabolic dysfunction triggers transcriptional
networks that reprogram steady-state hematopoiesis towards
persistent and myeloid-biased hematopoiesis.7,11 Therapeutic
targeting of PU.1 on adipocytes and adipose and liver macro-
phages improves glucose homeostasis and reduces liver steatosis,
inflammation, and fibrosis in mouse models of steatohepatitis,12
indicating that targeting regulators of emergency myelopoiesis in
patients with metabolic inflammation may revert pathologic
inflammation and restore tissue homeostasis. Evidencing a critical
contribution of dysregulated transcriptional networks of myelo-
poiesis and immunometabolism to the outcome of immunother-
apy, recent studies have shown that hyperglycemia and
hypercholesterolemia induce long-lasting changes in the tran-
scriptional landscape of HSCs and myeloid progenitors (MPs),
which perturb myeloid lineage fate decisions and the functional
polarization of myeloid cells,13,14 and these changes persist even
after changing to a control diet and upon weight loss15,16. Studies
support this novel concept by showing that resistance to cancer
immunotherapy correlates with host intrinsic metabolic dysfunc-
tions such as hormone imbalance, IR, changes in glucose and lipid
metabolism and enhanced inflammatory mediators.17
Extensive research published in medical and scientific journals
has demonstrated that cancer cell-intrinsic metabolism hijacks the
regulation of antitumor immune signaling, contributing to
immunotherapy resistance.18,19 However, the role of aberrant
immune cell-intrinsic metabolism in immunotherapy resistance
remains poorly investigated to date.
As the majority of patients still show de novo or adaptive
resistance to current immunotherapies, identifying immunometa-
bolic checkpoints that coordinate myelopoiesis and effector
lymphoid responses to oscillations in metabolites and inflamma-
tory signals has become a hot research topic for improving cancer
immunotherapy and preventing immune-related adverse events
(iRAES). In accordance with this scenario, increasing evidence
shows dysregulated cellular signaling and metabolism in myeloid
cell subsets that infiltrate immunologically cold tumors resistant to
immune checkpoint inhibitors (ICIs), chemotherapy (CT), and
radiotherapy, with the infiltrates characterized by a lack of T and
NK cell infiltrates, and accumulation of MDSCs, TAMs, and
tolerogenic DC.3,20
This review aims to highlight potential targets for myeloid
therapy, with a specific focus on recent efforts combining
myeloid-targeted immune therapy with strategies to restore
metabolic homeostasis.
INTERCONNECTION BETWEEN METABOLIC SYNDROME AND
INFLAMMATION
Metabolic syndrome is a collection of disturbances, including
glucose intolerance, obesity, hypertension, and dyslipidemia,21
with increasing prevalence in developed countries. Chronic low-
grade inflammatory conditions have been implicated as a major
factor for metabolic syndrome,22 which is accompanied by
metabolically triggered inflammation,23 a condition that does
not completely fit into the classical definition of acute or chronic
inflammation. Systemic metabolic inflammation accelerates
immune overactivation and dysregulation and can support
profound immune deficiency. This dual role of metabolic
inflammation suggests that the plasticity of immune responses
is intricately linked to the intracellular metabolism of immune cells
and is highly sensitive to systemic and local metabolic oscillations
in tissues.
Recent findings have highlighted the substantial impact that
metabolic syndrome has on lymphoid tissue integrity, lymphocyte
development, phenotypes and activity, and the coordination of
innate and adaptive immune responses. Importantly, these
changes are associated with an overall negative impact on
relapse-free survival in cancer patients.24,25 How exogenous and
intrinsic metabolic signals affect the immune response in patients
is poorly understood to date. Extensive clinical data and
experimental models demonstrate the involvement of obesity
and adipokines in the pathogenesis and treatment response of a
broad variety of autoimmune diseases.26 Hyper and persistent
secretion of inflammatory cytokines can cause IR in the adipose
tissue, skeletal muscle and liver by inhibiting insulin signal
transduction. Myeloid cells, primarily resident in colon, liver,
muscle, and adipose tissue, serve as a source of chronic
inflammation, termed meta-inflammation, causing localized IR
via autocrine/paracrine cytokine signaling and systemic IR via
endocrine cytokine signaling.27 In addition, meta-inflammation
predisposes patients to overactivated immune responses, with co-
occurring immune exhaustion and immunosuppression.28
Finally, the level of inflammation has a direct implication in
therapy, affecting the plasticity of the immune system. Indeed,
cancer therapy-induced inflammation (i.e., inflammation induced
by CT and radiotherapy) is considered an additional mechanism
reinforcing aberrant myelopoiesis. In this respect, IL-6 was shown
to activate emergency myelopoiesis after myeloablation conse-
quent to cytotoxic treatments.29,30 Furthermore, the use of
monoclonal antibodies (i.e., nivolumab) targeting checkpoint
inhibitors (i.e., PD-1) in cancer immunotherapy is frequently
associated with severe side effects, which are mitigated by anti-
inflammatory treatments, including steroids or the anti-IL-6
antibody tocilizumab in steroid-refractory patients.31 Combination
therapy with nivolumab+ ipilimumab was recently approved for
treating unresectable cases of malignant melanoma. Despite the
high response rate, this therapy is associated with a high
incidence of serious adverse events, including immune-related
hemophagocytic syndrome/hemophagocytic lymphohistiocytosis
(irHPS/HLH), macrophage activation syndrome, and secondary
HLH, a cytokine storm syndrome associated with multiorgan
system dysfunction and high mortality rates.32,33 Therefore,
understanding the role of inflammatory mediators and their
interconnection with patient metabolic status will be necessary to
ensure proper immunological manipulation and the best perso-
nalized therapies.
The controversial role of metabolic syndrome-associated myeloid
dysfunction in cancer
In response to immunologic stresses, including infection and
cancer, hematopoietic stem and progenitor cells in the bone
marrow (BM) sense peripheral inflammation and adapt through
increased proliferation and skewing towards the myeloid lineage.
Although these adaptations meet the need for more innate
immune cells, this lymphoid-myeloid switch and the enhanced
myelopoiesis might also perpetuate inflammatory and metabolic
disorders by generating a feed-forward loop between
inflammation-triggered MP cells and the inflamed tissue.4 Altera-
tions in MPs, as well as the expansion of pro-inflammatory
monocytes and MDSCs, also arise in high-fat diet (HFD)-induced
obesity34–36 and are considered a biomarker for the risk of obesity-
associated diseases, such as diabetes and atherosclerosis.37,38
Notably, it has been hypothesized that one of the mechanisms by
which obesity promotes cancer mortality is through the induction
of MDSCs.39–41 In accordance with this hypothesis, obese mice
with renal cancer develop a robust immunosuppressive environ-
ment that is characterized by heightened local and systemic
CCR2+ MDSC prevalence.42 In a pancreatic cancer mouse model of
diet-induced obesity, cells expressing common neutrophil and
MDSC markers (Gr1+CD11b+) were recruited to the pancreas by
adipocytes and pancreatic stellate cells producing the pro-
inflammatory mediator IL-1β. Depletion of Gr1+CD11b+ cells, IL-
1β, or pancreatic stellate cells prevented the rapid growth of
cancer in obesity.43 Similarly, in BALB/c mice carrying 4T1
mammary carcinoma, MDSCs from HFD mice were more
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immunosuppressive than MDSCs from low-fat diet (LFD) mice,
correlating with higher tumor progression and reduced survival,
and depletion of MDSCs in HFD mice restored activation of tumor-
reactive CD8+ T cells, reducing tumor progression, and sponta-
neous metastasis to levels comparable to those seen in LFD
mice.44 In addition to dampening the host-specific antitumor T cell
and DC immune responses, metabolic syndrome-associated
myeloid cells can drive pathologic overactivation of the immune
response. The increased risk of developing intra-abdominal
obesity and metabolic syndrome in the elderly population45 is
associated with hyperactivated macrophages, persistent myelo-
poiesis, and MDSC expansion, which paradoxically can drive a
deadly cytokine storm.46 This increase in inflammatory sensitivity
leads to a mixed immunophenotype of hyperactivated and
exhausted and tolerogenic immune cells that may predispose
individuals to infection or CAR-T cell cancer therapy-induced
cytokine storm. The role of MDSCs in immune dysregulation in
patients with metabolic syndrome remains controversial, as
MDSCs can also have beneficial effects and protect mice against
metabolic dysfunction and inflammation.47,48 Nevertheless, meta-
bolic syndrome-associated myeloid dysfunction, including the
expansion of MDSCs, has been associated with persistent and
unresolved myelopoiesis, leading to immune-mediated tissue
pathologies such as fibrosis, tumor angiogenesis, and metas-
tases.49 Therefore, therapeutic interventions that reprogram the
metabolism of MPs and myeloid cells in tumor patients towards
lineage fate decisions supporting myeloid effector and antigen-
presenting functions may restore immune-mediated tissue home-
ostasis and decrease the risk of disease relapse.
Metabolic cues can inform pathogenic myelopoiesis
Mounting evidence demonstrates a role for hypercholesterolemia
and hyperglycemia as factors that can independently regulate
HSPC function and/or alter the BM niche, influencing HSPC
proliferation and maturation.50–52 Hypercholesterolemia and
hyperglycemia promote leukocytosis, particularly of neutrophils
and monocytes.51,53,54 In addition, epigenetic mechanisms or
metabolic memory may permanently alter the functionality and
inflammatory status of HSPCs in diabetic patients, whose glucose
levels are inadequately controlled.55–57
The concordance of the changes in circulating progenitors and
leukocyte populations in diabetic mice and humans with diabetes
strongly suggests that BM myelopoiesis bridges the innate
immune response to metabolite oscillations. Supporting this view,
a newer study in a mouse model of obesity demonstrated that
chronically inflamed visceral adipose tissue, through enhanced
production of S100A8/A9, can signal to BM HSPCs to proliferate,
expand, and increase the production of myeloid cells.58 The
authors showed that in adipose tissue macrophages (ATM),
S100A8/A9 induces TLR4/MyD88- and NLRP3 inflammasome-
dependent production of IL-1β, which then travels to the BM to
induce the proliferation of hematopoietic progenitor cells via IL-
1R, ultimately resulting in monocytosis and neutrophilia.58 These
studies suggest that obesity may have life-long effects on
inflammatory responses by altering HSPC function and are
consistent with the observations that adipose tissue inflammation
and fibrosis are not resolved even after returning to normal
weight upon weight loss.15,16 Increasing evidence notes that a
western diet and lifestyle, as well as aging, drive the pandemic of
chronic noninfectious degenerative diseases, termed “civilization
diseases” (i.e., metabolic syndrome, cancer, and autoimmune and
neurodegenerative diseases), and dramatically increase the
susceptibility to and severity of infectious pandemics, such as
the current COVID-19 pandemic.59 Therefore, a better under-
standing of the immunometabolic signaling networks that
coordinate immune responses to environmental cues is war-
ranted, with the ultimate goal of identifying new therapeutic
strategies.
CANCER METABOLISM AND TRANSCRIPTIONAL CONTROL OF
EMERGENCY MYELOPOIESIS
In stress/pathological conditions (e.g., infection and cancer),
signals derived from the HSC niche modify the magnitude and
composition of the hematopoietic output, a feature of immune
regulation defined as “emergency” hematopoiesis, to guarantee a
proper supply of both lymphoid and myeloid cells in response to
increased demand.60,61 Most of the transcriptional mechanisms
that guide dysfunctional myelopoiesis in cancer patients have
been proven to be mechanistically linked to cancer-driven and/or
preexisting metabolic reprogramming of the host. Acquisition of a
tumor-supporting myeloid phenotype is the last event of a
multistep process, encompassing initial immunometabolic repro-
gramming of MPs in the BM and later steps of terminal
differentiation in the tumor microenvironment (TME), that occurs
through modulation of selected transcriptional activities.60
Role of orphan nuclear receptors (NRs) in metabolism-driven
myelopoiesis
Significant advances have been made in elucidating the molecular
mechanisms underlying the complex crosstalk between inflam-
mation and metabolism and the emergent role of ligand-activated
transcriptional regulators belonging to the NR superfamily,62
highlighting nutrient availability and intermediate metabolites as
the main orchestrators of stem cell behavior. A number of studies
have demonstrated a role of peroxisome proliferator-activated
receptors (PPARs) in controlling HSC specification and functional
polarization of myeloid cells through fine tuning of glucose and
lipid metabolism,63,64 implicating a metabolism-centric regulation
of lineage commitment.
We have demonstrated for the first time that myeloid-specific
expression of the retinoic acid-related orphan NR (RORC1/RORγ)
marks advanced cancer inflammation and that expansion of
circulating RORγ+ myeloid cells is associated with an increased
number of both immature suppressive cells (MDSCs) and TAMs.65
Ablation of RORγ in myeloid cells reprograms cancer myelopoiesis
in favor of effector APCs capable of inducing potent antitumor
CD4+ and CD8+ T cell responses and tumor regression.65
Interestingly, cholesterol precursors (i.e., desmosterol) and oxy-
sterols are known to be potent endogenous RORγ agonists,66,67
and RORγ has been shown to be an important player in the
circadian regulation of lipid and cholesterol metabolism.68 In
addition, RORγ has a key role in adipocyte differentiation and
mediating insulin sensitivity10 and is upregulated in patients with
severe obesity.69 Altogether, these studies suggest that myelopoi-
esis and myeloid lineage fate are tightly regulated by circadian
oscillations in metabolites. Therefore, profound changes in dietary
lipid composition and insulin sensitivity may contribute to
pathologic dysregulation of myelopoiesis and are one plausible
mechanistic link between cancer and obesity.
Role of myeloid transcription factors in metabolism-driven
myelopoiesis
Additional transcriptional mechanisms contribute to the metabolic
plasticity of myelopoiesis. CCAAT enhancer-binding protein-α (C/
EBPα) is a major regulator of “steady state” granulopoiesis70 that
interacts with the p50 NF-κB subunit to stimulate neutrophil
production during acute inflammation.71 Of note, the role of p50
NF-κB in the functional diversity of myeloid cells has been
delineated, demonstrating that its nuclear accumulation, in
response to tumor-derived prostaglandin E2 (PGE2), promotes
the suppressive phenotype of MDSCs and limits the antitumor
efficacy of ICIs.72 A recent study demonstrated that inhibition of
the NF-κB family member c-Rel transforms tumor-promoting
MDSCs into effector APCs, resulting in inhibition of CD4+CD25+
Treg cell expansion and consequent activation of potent
antitumor T cell responses, through metabolic reprogramming
via C/EBPβ.73 In contrast with C/EBPα, C/EBPβ 74, and signal
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transducer and activator of transcription 3 (STAT3)75 play major
roles in emergency conditions, contributing to MDSC accumula-
tion.76 Importantly, C/EBPβ accumulation contributes to β cell
failure and IR in mice by enhancing susceptibility to ER stress77
and is crucial in regulating diet-induced inflammation and
hyperlipidemia in hematopoietic cells and macrophages.78 Of
relevance, C/EBPβ expression is controlled by RORγ in cancer-
associated myeloid cells,65 thus indicating a RORγ-C/EBPβ axis as a
novel integrator of cancer myelopoiesis and lipid homeostasis.
These pioneering studies suggest that the myeloid transcriptome
and coordination of immune responses by myeloid cells are fine-
tuned to stress and environmental cues through metabolic
reprogramming.
NAD metabolism in myeloid cell mobilization and differentiation
Cancer cells display an atypical metabolic balance featuring
increased glucose uptake and fermentation of glucose to lactate,
even in the presence of oxygen and functioning mitochondria.79
This metabolic setting influences the crosstalk between tumor
cells and tumor-infiltrating immune cells, creating competition for
essential nutrients (glucose, in particular) and immunosuppres-
sion, which consequently hinder the therapeutic efficacy of
anticancer immunotherapy.80 TME metabolism requires the
cofactor nicotinamide adenine dinucleotide (NAD), which func-
tions in many critical redox processes necessary for cancer cells
and immune cells.81 Based on this, inhibitors of intracellular
nicotinamide phosphoribosyltransferase (iNAMPT), the rate-
limiting enzyme of NAD production in its salvage pathway, have
entered clinical trials for solid and nonsolid tumors due to their
ability to lower NAD and ATP levels and interfere with malignant
cell growth.82 We recently reported that M-CSF, in addition to
inducing PU.1-driven myeloid differentiation, has a direct role in
controlling iNAMPT activity. Elevated iNAMPT in MPs causes
negative regulation of the CXCR4 retention axis of hematopoietic
cells in the BM,83 thus disengaging these cells and allowing the
mobilization of suppressor myeloid cells to the periphery. In
agreement, iNAMPT inhibition prevents MDSC mobilization,
reactivates specific antitumor immunity, and enhances the
antitumor activity of ICIs83 (Fig. 1).
The system composed of iNAMPT and the NAD-dependent
protein deacetylase sirtuin 1 (SIRT1) plays a key role both in
maintaining correct energy metabolism and in enhancing the
robustness of physiological processes that control the resolution
of the inflammatory response.83,84 In this regard, emerging
evidence shows an age-related loss of iNAMPT/NAD+/SIRT1
activity that undermines antioxidant, metabolic and anti-
inflammatory systems.85,86 Furthermore, iNAMPT activity is neces-
sary for the differentiation of anti-inflammatory myeloid cells
under stress conditions.83 NAMPT converts nicotinamide into
nicotinamide mononucleotide (NMN), a precursor of NAD,87 which
is actively consumed by NAD-dependent enzymes (e.g., sirtuins,
mono-, and poly-(ADP-ribose) polymerases/ARTs and CD38/
CD157)84 that control a variety of metabolic and stress responses
through modulation of distinct transcriptional activities. In
particular, the deacetylase SIRT1 acts homeostatically by repres-
sing the transcription of HIF-1α-88 and p65 NF-κB-dependent
genes.89 Of relevance, SIRT1 was shown to promote alternative/
M2 macrophage polarization83,90 and suppressive activity of
MDSCs.91 Of note, C/EBPα and C/EBPβ are controlled by NAD
metabolism,92 indicating that in addition to insulin, glucose and
TDFs: CSFs, IL-1, IL-17,
metabolites (i.e. lactate)
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Fig. 1 Protumor reprogramming of myeloid cells. Tumor-derived factors (TDFs), including cytokines, myeloid growth factors and
metabolites, induce transcriptional activities (i.e., expression of cEBPβ, STAT3, p50, and RORC1/RORγ) guiding the enhanced proliferation and
lymphoid to myeloid switch of HSCs. In parallel, activation of CSF-dependent induction of iNAMPT provides enhanced NAD-dependent
activation of the sirtuin 1 deacetylase, which inhibits the HIF-1α-dependent and p65 NF-κB-dependent transcription of CXCR4. Deactivation
of the anchoring signal CXCR4 mobilizes myeloid cells from the bone marrow, allowing peripheral expansion of myeloid populations
(monocytes, neutrophils, MDSCs, and DCs). These cells reach the tumor site through the circulation and infiltrate the tumor tissue in
response to tumor-derived chemotactic signals (TDCFs) (i.e., CXCL2, CXCL8, CCL2, S100, VEGF, C5a, and CSF1). In particular, DCs and MDSCs
enter the secondary lymphoid organs (lymph nodes and spleen), eliciting inhibitory signals to T cells. Once in the tumor, myeloid cells
undergo a further step of reprogramming in response to inhibitory molecules (IL-10, TGFβ, adenosine, NO, and PD-L1) and
microenvironmental conditions (low glucose levels, hypoxia, and low pH), terminally differentiating into myeloid suppressor cells (TAMs,
TANs, MDSCs, and immature DCs). Overall, the tumor-dependent reprogramming of myeloid populations has to be considered a multistep
program, which comprises induction of emergency myelopoiesis (enhanced proliferation and the “lymphoid to myeloid” switch),
mobilization to the periphery and final intratumor reprogramming. Common myeloid precursors (CMPs), hematopoietic stem cells (HSCs),
tumor-derived factors (TDFs), immature DCs (iDCs)
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lipids, regulators of cellular redox reactions may play a key role in
myeloid homeostasis.
NAMPT expression is increased in various diseases, including
chronic inflammatory conditions (e.g., rheumatoid arthritis),
metabolic diseases (e.g., diabetes), and cancer.91 The robustness
of the NAMPT/NAD+/SIRT1 system is controlled by the nutritional
supply of tryptophan, and tryptophan and vitamin B3 (niacin)
enable the primary and rescue pathways for the synthesis of NAD,
respectively.87 Furthermore, administration of vitamin D3 to
tumor-bearing mice (bearing metastatic Lewis lung carcinoma)
reduces tumor-induced suppressor myeloid cells and enhances T
cell functions93 and the differentiation of CD34+ immature
myeloid cells.94 Importantly, recent studies have associated
increased levels of extracellular NAMPT/visfatin with overweight/
obesity, type 2 diabetes mellitus, IR, metabolic syndrome, and
cardiovascular disease.95 Therefore, a better understanding of
obesity-induced alterations in redox homeostasis and oxidative
stress may provide us with important novel immunotherapeutic
targets to reprogram pathogenic myelopoiesis in favor of effector
APCs capable of coordinating potent antitumor responses.
INTERACTIONS BETWEEN METABOLISM AND MYELOID CELL
ACTIVATION STATE
Of relevance, myeloid cells, macrophages in particular, express
different functional programs in response to microenvironmental
signals, a property defined as plasticity. The extremes of this
functional spectrum are generally defined as classical (M1) and
alternative (M2) activation states, which identify a cytotoxic and
inflammatory phenotype as opposed to an anti-inflammatory and
immunosuppressive phenotype, respectively.96 The shift between
these antithetical activation states plays a distinct role in disease
and has inspired new anticancer strategies aimed at the functional
reprogramming of myeloid cells.96 Notably, evidence indicates
that selected metabolic pathways can alter immune cell differ-
entiation and direct effector functions.97 In response to M1-
polarizing signals (i.e., LPS and IFNγ), macrophages fuel their
energy requirements by enhanced glycolysis, associated with high
flux through the pentose phosphate pathway, FA synthesis and a
truncated tricarboxylic acid cycle, leading to accumulation of
succinate and citrate.98 This metabolic profile induces the
activation of transcriptional factors (i.e., NF-κB and STAT1)
supporting the expression of a pro-inflammatory and antimicro-
bial program.96 Conversely, in response to IL-4, M2-polarized
macrophages obtain energy through oxidative phosphorylation
(OXPHOS)99 and fatty acid oxidation (FAO). In agreement, STAT6-
dependent upregulation of the transcription factors peroxisome
PPAR γ-coactivator-1β, PPARγ, and PPARδ drives the expression of
genes that are crucial promoters of both oxidative metabolism
and anti-inflammatory activities.100–102
In addition to macrophages, DCs and neutrophils are strongly
affected by metabolic cues. DCs are the most potent antigen-
presenting cells (APCs) of the immune system, and their
phenotype is influenced by inflammatory and metabolic dis-
orders.103 Tumors alter host hematopoiesis and induce an
immature DC phenotype with immune-suppressive properties. In
particular, cancer cell-derived immune-suppressive factors (VEGF,
IL-10, and PGE2) disable DC differentiation, maturation, migration,
and functions.104 Furthermore, lipid and amino acid metabolism
modulate DC functions. Of relevance, while 27 hydroxycholesterol
acts on HSCs via estrogen receptor α to increase their proliferation
and mobilization,105 oxysterols, which are produced through
enzymatic and nonenzymatic oxidation of cholesterol,106 interact
with liver X receptors exerting an anti-inflammatory role on
DCs.107 In agreement, oxysterols produced by tumor cells impair
antigen presentation by inhibiting CCR7 expression on DCs.108 DC
functionality can also be compromised by the uptake of lipids
enriched within the TME, which lead to DC dysfunctions.109
Furthermore, DC immunogenicity is hampered by both TAMs and
MDSCs through the production of copious amounts of indolea-
mine 2,3-dioxygenase 1 (IDO1), which converts tryptophan into
kynurenines (Kyns).110 The metabolic plasticity of DCs is particu-
larly evident during their progression from an immature to a
mature state. Immature DCs generate ATP through OXPHOS, a
process primarily driven by FAO.111 In response to maturation
signals, DCs undergo a metabolic shift towards glycolysis.112 DC
commitment to glycolysis correlates with activation of HIF-1,
which is necessary to enhance the expression of glycolytic
enzymes.113 Nevertheless, several tumors actively inhibit glycolysis
and lipid synthesis in these cells, exacerbating impaired metabolic
and immunologic functions of DC.114
The disrupted metabolic flux of cancer cells, characterized by
aerobic glycolysis (Warburg effect), results in the preferential
conversion of pyruvate to lactate, which in turn impairs the
maturation of DCs115 and M2 polarization of TAMs.116 Adenosine
production by tumors is an additional mechanism that impairs DC
antitumor activities.117 Mechanistically, adenosine promotes the
accumulation of cAMP in DCs and the consequent activation of
the PKA and Epac pathways that polarize these cells to a tumor-
promoting phenotype (IL-10high/IL-12low).118 Notably, the antitu-
mor activity of CT has also been attributed to the induction of
“immunogenic cancer-cell death”, which favors the processing
and presentation of dead cell-associated antigens by DCs.119
Neutrophils have a short half-life of 7–10 h in both humans and
mice.120 In accordance with their high turnover rates and rapid
adaptability to diverse conditions of the tissue microenvironment,
a number of studies have demonstrated their functional plasticity
and capacity to extend their life in response to cytokines (i.e., IL-
1β, IL-6, and TNF) and granulocyte colony-stimulating factor (G-
CSF).121,122 Tumor-associated neutrophils (TANs) can elicit cyto-
toxic activity against tumor cells and promote inhibition of
metastasis.123 However, contrasting evidence suggests that TANs
can support tumor angiogenesis, cancer cell migration and
invasion and immunosuppression.120 According to these results,
IL-1β-driven IL-17 expression by γδ T cells promoted TAN
expansion in mammary cancer-bearing mice, which eventually
suppressed cytotoxic CD8+ T cell functions.124 Furthermore, PD-
L1+ neutrophils from patients with hepatocellular carcinoma
effectively suppressed the proliferation and activation of CD4+
and CD8+ T cells via PD-1/PD-L1 interactions.125 Of relevance, a
high neutrophil-to-lymphocyte ratio (NLR) correlates with poor
clinical outcome in patients with advanced-stage cancers,126 and a
recent meta-analysis on 39 different malignancies identified
tumor-infiltrating neutrophils as the immune population asso-
ciated with the worst prognosis.127 In line with these contrasting
observations, a recent paradigm has highlighted the phenotypic
plasticity of TANs, which in response to microenvironmental
signals can either display an inflammatory (N1) or an alternative
(N2), tumor-promoting activation state. Transforming growth
factor-β (TGFβ) was demonstrated to promote the N2 phenotype,
whereas interferon-β leads to an antitumor (or N1) phenotype.128
Neutrophils are highly dependent on HIF-1 regulation, and in
general, hypoxic conditions increase neutrophil inflammatory
functions,129,130 promoting tissue infiltration, survival, activation,
and cytokine release. In agreement, evidence indicates that
neutrophils can suppress CTLs via HIF-1α-dependent131 iNOS-
mediated nitric oxide (NO) production and reactive oxygen
species (ROS).124
Amino acid metabolism and suppressor myeloid cells
Consumption of essential amino acids is a classic example of how
tumors exploit metabolic pathways to generate molecules
endowed with immunomodulatory activities and deplete nutri-
ents essential for T cells. In particular, TAMs and MDSCs express
high levels of IDO1, an enzyme that converts tryptophan into its
immunosuppressive catabolite Kyn, which is capable of inducing
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
L Strauss et al.
5
Cellular & Molecular Immunology _#####################_
the expansion of regulatory T (Treg) cells,80 depriving T cells of an
essential nutrient132 and hindering the immunogenicity of DCs.110
L-arginine depletion is one of the main mechanisms by which
MDSCs inhibit antitumoral T cell activity; however, granulocytic
(PMN-MDSCs) and monocytic (M-MDSCs) subsets of MDSCs use
distinct enzymes or arginine metabolism to generate immuno-
suppression. In particular, L-arginine depletion by ARG1 predomi-
nantly occurs in PMN-MDSCs and leads to downregulation of T cell
receptor (TCR)-ζ chain expression and inhibition of the cyclin-
dependent kinase pathway regulating the cell cycle,133 as well as
downregulation of the ornithine and polyamine generation that
supports tumor cell proliferation.134 In contrast, M-MDSCs utilize
the nitric oxide synthase (iNOS) enzyme to produce NO and
promote tyrosine nitration and S-cysteine nitrosation of various
proteins.135,136 Several lines of evidence also indicate that both
enzymes can contribute to the immunosuppressive activities of
human MDSCs.1
Cysteine represents an additional essential nutrient for T cells
that is introduced from the extracellular space. In contrast with
APCs that import extracellular oxidized cystine and export the
cysteine used by T cells, MDSCs only uptake cystine (using the AA
antiporter xc), thus limiting the extracellular pool of cysteine
required for T cell activation.137
HOST INSULIN METABOLISM AND CANCER PROGRESSION
In the early 1990s, the role of TNF-α as a pro-inflammatory
cytokine linked to IR was demonstrated in the adipose tissue of
obese mice.138 Later, studies in healthy and obese subjects
confirmed that pro-inflammatory cytokines and immune cell
infiltration were involved in glucose homeostasis.139 These
findings raised interest in the potential role of IR in obesity-
induced chronic inflammation, which is now known to be
associated with cancer development and aggressiveness.140 The
relationship between insulin, insulin sensitivity, the insulin growth
factor (IGF) receptor family and cancer is now well established.
Insulin and insulin-like growth factor 1 (IGF-1) activate insulin
receptor and IGF-1 receptor, respectively, which are expressed at
higher levels in malignant cells and support their proliferation.141
In addition, both insulin and IGF-1 increase sex hormone synthesis
and reduce sex hormone-binding globulin levels, leading to
elevated levels of estrogens and other endocrine tumor promo-
ters.141 Moreover, obesity itself has been hypothesized to
adversely impact the response to CT, not only through metabolic
perturbations and underlying IR, adipokine production, and the
IGF-1 axis but also by affecting drug delivery, pharmacokinetics,
and transport.142 Of relevance, the obesity-driven transition of the
macrophage activation state from “M2-like” to “M1-like” promotes
inflammation and potentially contributes to IR.143 Macrophages
are very prominent in adipose tissue, where they can reach
proportions of up to 50% of all cells.144 Within breast adipose
tissue, obesity leads to chronic, macrophage-driven inflammation,
suggesting that obese breast cancer patients may benefit from
metabolic targeting.145 In general, the inflammatory state induced
by neoplastic processes might increase the cancer cell prolifera-
tion and paracrine-related effects mediated by inflammatory
cytokines, such as increased angiogenesis146 and myeloid cell
accumulation (TAMs and MDSCs), which orchestrate the creation
of an immunosuppressive environment.147
Epidemiological observations have provided evidence that
higher circulating insulin levels are associated with an adverse
outcome in early BC patients.148,149 From this perspective, the
insulin pathway may represent a therapeutic target, especially in
patients with high plasma insulin levels. Hyperinsulinemia may
reflect an altered level of insulin sensitivity and be associated with
chronic inflammation, characterized by high levels of IL-6, C-
reactive protein, tumor necrosis factor-α, fibrinogen, and the cell
adhesion molecules ICAM-1 and VCAM-1.150 Moreover,
hyperinsulinemia induces proliferative tissue abnormalities due
to strong anabolic effects, resulting in the enhancement of DNA
synthesis and cell proliferation. In women with early BC without
diabetes, it has been observed that hyperinsulinemia is associated
with the presence of IR.151 In our recent publication, we
hypothesized that insulin might exert its influence on tumor
aggressiveness by modulating gene expression at the level of
breast cancer cells. In particular, by using publicly available gene
datasets, we recently identified a gene signature based on the
differential expression of 15 genes related to the insulin (27%),
chronic inflammation (30%), and IGF pathways (40%) that was
strongly associated with disease-free survival in early breast
cancer.152 These data suggest that it is possible to identify a
subset of BC patients whose prognosis is modulated by a set of
genes related to the insulin pathway.
From this perspective, the potential antitumor effect of the
antidiabetic drug metformin has been extensively studied due to
its antiproliferative activity in vitro.153,154 In cancer patients,
however, metabolic targeting does not translate into a measurable
clinical benefit, probably due to the complexity of the IGF-1R/
insulin receptor system and the presence of parallel pathways of
growth and survival, as well as the lack of appropriate patient
selection markers.154,155 Moreover, a number of clinical studies
evaluating anti-IGF drugs (either monoclonal antibodies or TKIs)
reported inconsistent results or were complicated by excessive
metabolic toxicity (hyperglycemia). We recently performed a
translational study to evaluate the potential role of IGF-1R
expression on circulating tumor cells (CTCs) of patients enrolled
in the MYME trial, which compares first-line CT with first-line CT
plus metformin in HER2-negative, metastatic BC patients without
diabetes. Our data demonstrate that patients with loss of IGF-1R
on CTCs have a significantly worse outcome than patients with
IGF-1R expression on CTCs, providing a possible clue for improved
patient stratification strategies aimed at metabolic targeting in
advanced BC.152 Overall, the relationship between IR, metabolic
impairment, the underlying chronic inflammatory status and
cancer needs to be extensively evaluated to better develop a
strategy for “metabolic targeting”.
Additional studies addressing the impact of obesity and IR on
the outcome of ICI therapy have provided controversial data to
date. ICIs have been reported to cause immune-mediated damage
to islet cells, leading to ICI-induced type 1 diabetes mellitus
(T1DM).156 On the other hand, there are a number of reports
supporting an “obesity paradox,” in which patients with higher
body mass index, i.e., patients with overweight or obesity, have an
improved outcome if treated with immunotherapy for advanced
tumors,157 indicating a close connection between the immune
system and patient metabolic status. Stratifying a cohort of
patients with metastatic melanoma into groups based on receipt
of first-line immunotherapy revealed a moderate but insignificant
association between overweight or obesity and better
progression-free survival in patients who received first-line
immunotherapy. Conversely, an association with worse
progression-free survival was observed in patients who received
non-first-line ICIs.158 Therefore, studies that better depict the
contribution of IR and obesity to the outcome of ICI therapy are
needed to adapt patient care to metabolic status.
Tumors alter the glycolysis vs. OXPHOS balance of myeloid cells to
control their activation state
Recent studies indicate that impaired OXPHOS accompanied by
increased glycolysis may be a significant contributor to increased
myelopoiesis and heightened myeloid cell activation under acute
and chronic settings.159,160 Enhanced tumor glycolytic flux
converts a major fraction of pyruvate into lactate, even under
normoxic conditions (Warburg effect). The conversion of pyruvate
into lactate is mediated by lactate dehydrogenase A, a hypoxia-
inducible factor 1α (HIF-1α) target.161,162 Lactate-mediated
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inhibition of DC maturation115 is paralleled by the generation of
MDSCs.162 Moreover, a recent study suggests that lactate operates
as an endogenous inhibitor of histone deacetylases,163 transcrip-
tionally regulating a number of genes that not only are involved in
metabolism and transcriptional control but also participate in
immune response fate. Furthermore, increased tumor glycolysis
enhances GM-CSF, G-CSF, C/EBPβ164, and NF-κB expression,165
which represent major immune signaling pathways that support
MDSC differentiation.
In addition to the competition for glucose and essential
metabolites in inflamed tissue, intracellular metabolic aberrations
may reprogram immune cell fate, survival and function. A new
study shows that tumor MDSCs suppress glycolysis-mediated T
cell effector functions by transferring methylglyoxal to CD8+
T cells via direct cell contact. The acquisition of methylglyoxal by
T cells coincides with a reduction in free L-arginine and a
concomitant increase in the products of glycation reactions
between methylglyoxal and L-arginine, suggesting that depletion
of L-arginine in the cytosol paralyzes T cell functions.166 Under
homeostatic conditions, cells are protected against methylglyoxal
toxicity by different mechanisms, particularly the glyoxalase
system, which represents the most important pathway for the
detoxification of methylglyoxal.167 Methylglyoxal is formed as a
byproduct of glycolysis and is a major cell-permeant precursor of
advanced glycation end-products (AGEs), while engagement of
RAGE, the receptor for AGEs, is shown to activate downstream
signaling and evoke oxidative stress and inflammation in
diabetes.168 Changes in the intracellular levels of glycolytic
metabolites are linked to the inflammatory phenotype of immune
cells implicated in autoimmune disorders, such as systemic lupus
erythematosus, rheumatoid arthritis, multiple sclerosis, and
diabetes. Notably, targeting metabolic effectors, such as targeting
of mTOR by rapamycin, hexokinase by 2-deoxy-D-glucose, and
adenosine monophosphate (AMP)-activated protein kinase by
metformin, may be used to ameliorate autoimmune
inflammation.169,170 Preliminary studies suggest that extrinsic
and intrinsic increases in glycolysis and uncoupling from OXPHOS
may lead to aberrant myeloid cell differentiation, expansion, and
activation in a broad range of inflammatory diseases.
INTERPLAY BETWEEN CANCER THERAPY, METABOLISM, AND
MYELOID SUPPRESSOR CELLS
Deregulated myelopoiesis sustains malignant transformation and
progression by shaping the TME via interactions with tumor cells,
stroma, and other infiltrating immune cells, ultimately promoting
cell growth, angiogenesis, and diversion and skewing of the
adaptive immune response. The generation of suppressor myeloid
cells is a driving force for tumor progression and therefore a
promising therapeutic target. In addition, available anticancer
strategies feature myeloid-specific activities as part of their
antitumor actions. In particular, modulation of MDSCs is now
accredited as a key therapeutic strategy due to the tumor-
promoting phenotype of MDSCs and their capacity to affect the
efficacy of CT, radiotherapy, and immunotherapy.
Metabolic effects of cancer therapy
Newer studies have shown that cancer treatment-induced
metabolic syndrome (CTIMetS) is an especially prevalent and
harmful side effect of CT. Long-term survivors of childhood, breast,
colorectal and testicular cancer, and of several hematological
malignancies face an increased risk of treatment-induced cardi-
ovascular disease171 and metabolic syndrome.172 Metabolic
comorbidities may adversely affect patient survival and quality
of life and might be an important link between cancer treatment
cardiovascular toxicity and accelerated atherosclerosis in cancer
survivors.173 Obesity is a contributing factor to the higher
occurrence of metabolic syndrome and cardiovascular morbidity
in cancer survivors.174 In addition, IR may be driven by CT.
Alkylators, anthracyclines, camptothecins (e.g., irinotecan), epipo-
dophyllotoxins (e.g., etoposide), and platinum-based treatments
may drive IR due to mitochondrial dysfunction through increased
production of ROS.175 Antimetabolites such as capecitabine can
decrease hepatic lipid export, causing steatosis, which is
associated with decreased insulin sensitivity.176 Furthermore,
anemia, which is a common side effect of anticancer treatments,
may cause adipose tissue hypoxia, leading to macrophage
activation and inflammatory cytokine release.175 Therefore, CT
contributes to the development of CTIMetS mostly through
weight gain but may also indirectly affect other metabolic
syndrome components, such as dyslipidemia or IR.
Although the etiology of metabolic syndrome in noncancer
patients probably differs from the etiology in cancer patients
treated with conventional cancer therapy,172 the same treatment
strategies to restore metabolic homeostasis may have similar
positive effects on the prevention and treatment of the different
components of metabolic syndrome and improvement of life
quality and life expectancy.
Interestingly, in premenopausal and postmenopausal early
breast cancer patients with no preexisting metabolic syndrome,
adjuvant, or neoadjuvant CT was associated with an increased
prevalence of metabolic syndrome and related anthropometrics,
biomarkers of glucose metabolism, and inflammation.177 Identify-
ing markers able to capture the complex interplay among host
metabolism, myelopoiesis, CT, and the TME might contribute to
integrating preclinical and clinical research.
Cranial and abdominal radiotherapy are major risk factors for
obesity, dyslipidemia, and IR in childhood cancer survivors.178,179
The pancreas has always been considered relatively insensitive to
radiation.180 However, recent evidence suggests that radiation
may induce apoptosis of pancreatic beta cells and consequently
decrease insulin production, leading to hyperglycemia, elevated
FFA levels, hypertriglyceridemia, and IR.179,181 Deficiency of
growth hormone is the most common endocrine dysfunction in
patients treated with cranial radiotherapy and is associated with
obesity, dyslipidemia, and IR.182 Growth hormone contributes to
lipolysis and has an insulin-like influence because of its relation-
ship with the production of IGF-1, which results in glucose
uptake.172 Preliminary data suggest that assessment of metabolic
fitness and myeloid function may be critical to avoid iRAEs and to
increase the efficacy of conventional cancer therapy. MDSC levels
may be used as a novel biomarker for metabolic syndrome and
related immune dysfunction, as MDSCs are the end product of
profound cellular metabolic changes.
Chemotherapy (CT) and MDSCs
CT is a long-standing inclusion in the therapeutic armamentarium
against cancer. Mounting evidence from preclinical studies has
revealed the contribution of the host immune system to the
efficacy of several anticancer drugs. Most preclinical studies
support CT-induced inflammation as a mechanism to reinforce
aberrant myelopoiesis, which serves as a counterregulatory
adaptation to prevent unnecessary damage from chemical
insult.183 Enhancement of MDSC suppressive activity is described
with doxorubicin and with high-dose cyclophosphamide, among
other treatments.184 In contrast, other preclinical data have shown
that a number of cytotoxic agents, including docetaxel, 5-
fluorouracil, and gemcitabine, can induce MDSC apoptosis.185–187
Treatment with cyclophosphamide can be considered a prime
example of the complexity of the interplay between CT and the
immune system, since both immunostimulating effects and the
induction of immunosuppressive cells have been described with
this agent.188–192
In breast cancer, data from clinical studies prospectively
evaluating the effects of CT on MDSCs are scant, and the results
are somewhat conflicting.193–195 However, these data are far from
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conclusive, considering the limited sample sizes, the heterogene-
ity of the patient populations (in terms of breast cancer phenotype
classified according to hormone receptor and HER2 expression), as
well as differences in G-CSF use, which is one of the key drivers of
aberrant expansion of myeloid cells.
In patients with advanced pancreatic cancer, MDSCs are
significantly elevated compared to the numbers in healthy
controls.196 In a pilot nonrandomized trial, MDSCs were signifi-
cantly decreased in patients treated with the combination of
gemcitabine and omega 3 fatty acid, while no significant change
was observed in patients treated with gemcitabine alone.
Intriguingly, better progression-free survival was reported for
patients treated with the combination. However, these findings
should be interpreted with caution due to the nonrandomized
nature of the study.197
In patients with nonmetastatic urothelial cancer of the bladder
undergoing radical cystectomy, the percentages of total MDSCs
and PMN-MDSCs in PBMCs were significantly lower in patients
achieving a pathologic complete response than patients showing
no response. Higher levels of MDSCs before surgery were also
associated with worse overall survival.198
In patients with non-small-cell lung cancer receiving first-line
platinum-based CT, a significantly worse outcome was reported
for patients with higher M-MDSCs than for those with lower M-
MDSCs. However, dynamic changes in MDSCs during CT were not
evaluated.199 Overall, these data suggest that CT can impact the
TME by promoting an antitumor immune response or by inducing
MDSCs that counterregulate the immune response.
Myeloid immunometabolism and immunotherapy
CT and radiotherapy still represent fundamental strategies in
anticancer treatment. Nevertheless, in the past few years, restoring
the immune response with ICIs has emerged as an effective
strategy across different cancer types. Interestingly, though
apparently counterproductive from a theoretical standpoint, the
combination of these two strategies has resulted in clinically
meaningful results.200–203 However, the magnitude of clinical
benefit with immunotherapy is heterogeneous, since a significant
proportion of patients do not respond or even experience
hyperprogression.204 In this context, circulating immune-related
biomarkers are particularly attractive. Cancer mortality is almost
doubled in patients with elevated MDSCs.205 It has been reported
that the presence of circulating MDSCs predicts higher stage and
worse survival rates206 and increases the risk of resistance to ICIs.207
Measuring MDSCs is a novel and yet-to-be-exploited strategy for
treating cancer. MDSCs are difficult to detect and quantify because
their phenotypic signature includes multiple surface markers
studied by flow cytometry or immunohistochemistry, and those
markers can detect immature myeloid cells but cannot predict
suppressor function. A consensus phenotype of human MDSCs has
recently emerged208,209 and can predict dysregulated myelopoiesis
when evaluated together with clinical parameters.
The importance of MDSCs in promoting resistance to immu-
notherapy was not recognized until the first studies demonstrated
that MDSCs have potent utility in inhibiting T cell and NK cell
activity, contributing to resistance to immunotherapy and
predicting resistance to ICIs.210 To date, the majority of the clinical
data are available for melanoma patients treated with ipilimumab,
in which a potential role of the frequency of monocytic MDSCs as
a predictive marker of response has been suggested.211 In another
study assessing the frequencies of MDSCs and Treg cells in 209
melanoma patients treated with ipilimumab, MDSC frequencies
and CD4+CD25+FoxP3+ Treg cell frequencies were significantly
associated with survival.207 In prostate cancer patients treated
with ipilimumab combined with a cancer vaccine, a lower
frequency of circulating MDSCs was found to correlate with an
increased overall survival.212 Several ongoing trials of chemoim-
munotherapy are prospectively evaluating MDSCs and TAMs, with
the aim of elucidating the mechanisms underlying different
patterns of response and different outcomes upon treatment. In
line with these studies, the field of cancer immunotherapy has
focused on developing therapeutic strategies to eliminate MDSCs.
Tumor-infiltrating lymphocytes (TILs) are critical for inducing
tumor regression; however, TILs in patients with “cold” myeloid-
driven tumors are not sufficient to overcome tumor-associated
immunosuppression. It is becoming clear that eliminating
inflammation-driven emergency myelopoiesis is critical for
enabling improved T effector-APC crosstalk, recruitment of
antitumor immune responses, and inhibition of tumor-
promoting angiogenesis. Emerging studies support the view that
targeting tumor metabolism in combination with immunotherapy
enhances the efficacy of immunotherapy.
In mice, inhibition of FAO significantly decreases FA uptake and
inhibits the immunosuppressive function of MDSCs at the tumor
site in Lewis lung carcinoma (3LL).40 All-trans retinoic acid (ATRA),
a metabolite of vitamin A, induces MDSCs to differentiate into
APCs as well as myeloid maturation, which correlate with an
improvement of the antitumor effector T cell response213 and
reduced MDSC levels in tumor-bearing mice and tumor
patients.214,215 ATRA affects MDSCs by upregulating the expres-
sion of glutathione through ERK1/2 activation to neutralize a large
amount of ROS in MDSCs and promote MDSC differentiation.216
Inhibition of glucose uptake by a Glut1 inhibitor to inhibit
exacerbated glycolysis in stroma cells, MPs and myeloid cells may
provide a novel therapeutic approach to prevent myelopoiesis-
driven inflammatory diseases.217 AMP-activated protein kinase
(AMPK) activation can inhibit several major immune signaling
pathways, e.g., the JAK-STAT, NF-κB, C/EBPβ, CHOP, and HIF-1α
pathways. Activation of these pathways regulates cellular immu-
nity in cooperation with pathways controlling energy metabolism,
which favor the expansion and activation of MDSCs.165 Further-
more, a recent study by Strauss et al. showed that immune
checkpoints such as PD-1 suppress the differentiation of MPs to
effector APCs and promote the expansion of MDSCs through
metabolic reprogramming of myeloid precursors.218 Metformin, a
widely used drug in treating and curing type II diabetes, has been
proven to reduce the incidence of cancers, reduce mortality,
increase the response to radiotherapy and CT, optimize tumor cell
migration, and reduce the likelihood of relapse.219 Metformin
inhibits mTOR activity by activating ATM (ataxia telangiectasia
mutated) and LKB1 (liver kinase B1) and AMP-activated kinase
(AMPK), thus preventing protein synthesis and cell growth,219 as
well as MDSC expansion.220,221 Taken together, these findings
provide a rationale for combining strategies reprogramming the
metabolism of MDSCs with immunotherapeutic strategies in
cancer treatment and prevention.
Recent data have highlighted the crucial connection between
metabolism and cancer immunotherapy. In particular, a new
experimental glutamine antagonist has been shown to induce
tumor regression not only through cancer cell starvation but also
by activating effector T cells, thus dismantling the immunosup-
pressive TME. Indeed, T cells respond to glutamine antagonism by
markedly upregulating oxidative metabolism and adopting a long-
lived, highly activated phenotype. Exploiting different metabolic
states of the components of the TME might contribute to
improving the therapeutic armamentarium against cancer.222
CONCLUDING REMARKS
The ability of the immune system as well as adipose tissue to
expand and contract in response to fluctuations in nutrient
availability is essential for the maintenance of whole-body home-
ostasis. Given the shortages of nutrients that mammals have faced
for millions of years, the current programs involved in immune and
adipose plasticity likely evolved to be highly efficient in promoting
metabolic strategies to adapt to nutrient stress. Therefore, it is not
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surprising that many transcription networks critical for innate and
adaptive immune cell functions are shared by adipose tissue and
have a role in insulin signaling. Myelopoiesis, as the host first line of
defense, requires very high plasticity and therefore shares many
transcription and cytokine networks with adipocytes, and these
networks provide MPs and myeloid cells with extra metabolites in
response to environmental cues. Tumors perturb these adaptive
networks by consuming oxygen and critical metabolites for immune
and stromal cell function. In addition, these previously advantageous
features may now represent a metabolic risk factor given the caloric
excess of modern society. Acquisition of a tumor-promoting
phenotype by myeloid cells as well as stress-triggered adipogenesis
and IR are the results of a multistep process encompassing initial
events originating in the BM and later steps operating in the TME.60
The interplay between inflammation and metabolism dictates
transcriptional programs supporting the differentiation of myeloid
suppressor cells (MDSCs, iDCs, and TAMs). These cells are being
recognized as novel biomarkers for metabolism-compromised
dysregulation of central tissue homeostasis, which leads to systemic
immune dysfunction and persistent inflammation in cancer and
metabolic syndrome-related inflammatory diseases (Fig. 2). Recent
research highlights the potential therapeutic impact of targeting
specific metabolic pathways and/or modifying the quantity and
quality of myeloid output to stimulate anticancer immunosurveil-
lance and prevent disease relapse. New studies are now required to
carefully evaluate the myelopoietic and immunomodulatory impact
of anticancer therapies, as well as their interplay with host
immunometabolism. Immunometabolic characterization of the
population of interest, cancer patients in particular, should therefore
be sponsored, as it might establish new criteria for stratification of
patients and therapeutic interventions. A lack of proactive and
preventive efforts could lead to worldwide permeation of such
immunometabolic dysfunctions, with an increased risk of develop-
ing resistance to and irAEs with immunotherapy and a consequent
reduction in therapeutic options.
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Fig. 2 Interconnections between metabolism, cancer-related inflammation, myelopoiesis, and cancer therapy. Obesity and adipose tissue
macrophages (ATMs) promote myeloid cell expansion by releasing various inflammatory cytokines and adipokines that activate selected
transcriptional activities (PARs, RORC1/RORγ, and C/EBPβ) affecting HSC proliferation and differentiation. This myelopoietic boost is amplified
by cancer cells that release additional myelopoietic factors, including CSFs, IL-1, IL-17, and PGE2. These factors induce myelopoiesis through
the upregulation of specialized transcription factors (i.e., p50 NF-κB, STAT3, and PU-1). The production of adenosine, VEGF, and IL-10 by cancer
cells induces the tumor-promoting phenotype (IL-10high/IL-12low) of iDCs. The emerging myeloid populations are then recruited to the tumor
site, where they acquire suppressor phenotypes (TAMs, TANs, MDSCs, and iDCs) and establish an immunosuppressed tumor
microenvironment (TME). The tumor site actively hinders the activation of T lymphocytes through the depletion of amino acids, orchestrated
by both infiltrating myeloid suppressor cells and cancer cells that express immunosuppressive enzymes (IDO, iNOS, and Arg1). IDO activity, in
particular, results in the production of the immunosuppressive catabolite kynurenine (Kyn), which is capable of inducing the expansion of
regulatory T (Treg) cells. Further expression of immune checkpoint ligands (i.e., PD-L1) by myeloid suppressor cells contributes to the
inhibition of antitumor immunity. The metabolic consequences of obesity also drive the transition of macrophages from “M2-like” to “M1-like”
activation, contributing to inflammation-driven insulin resistance (IR). Of note, both obesity and select chemotherapeutics (i.e., irinotecan,
etoposide, and platinum) can induce IR, interfere with the energetic balance and affect T cell activation. However, chemotherapy can also
enhance antitumor immunity by promoting the immunogenic cell death (ICD) of cancer cells (i.e., anthracyclines, DNA-damaging agents) and
by depleting MDSCs (i.e., docetaxel, gemcitabine, and 5-fluorouracil). In line with this, the inhibition of FAO significantly decreases FA uptake
and inhibits the immunosuppressive function of MDSCs. Globally, the intersection of the host’s metabolic status, tumor metabolism, cancer
inflammation and the quality of myelopoietic output strongly influences the response to therapy. ICD immunogenic cell death, IR insulin
resistance, FAO fatty acid oxidation, FA fatty acid
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